Point72 Asset Management
NKTR icon

Point72 Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Point72 Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,000
Closed -$381K – 4252
2025
Q4 		$381K Sell
9,000
-23,500
-72% -$1.32M ﹤0.01% 3373
2025
Q3 		$1.85M Buy
+32,500
New +$1.08M ﹤0.01% 1471
2019
Q4 		– Sell
-5,533
Closed -$1.51M – 1151
2019
Q3 		$1.51M Buy
+5,533
New +$2.03M 0.01% 630

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Point72 Asset Management's NKTR Position: Q1 2026 in Review

Point72 Asset Management reduced its Nektar Therapeutics (NKTR) stake by 97% in Q1 2026, selling an estimated $23.9M and leaving 13,364 shares worth $962K. The position accounts for ﹤0.01% of the portfolio, ranked #2781.

Point72 Asset Management first reported a position in NKTR in Q3 2015 and has held it in 13 quarters since. The position peaked at $18.3M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Point72 Asset Management held 13,364 shares of Nektar Therapeutics worth $962K as of Q1 2026.
  • Point72 Asset Management sold 420,055 Nektar Therapeutics shares in Q1 2026, an estimated $23.9M.
  • Nektar Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2781 holding.
  • Point72 Asset Management first reported a position in Nektar Therapeutics in Q3 2015 and has held it in 13 quarters since.
  • Point72 Asset Management's Nektar Therapeutics position peaked at $18.3M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.